Trends in Lower Limb Revascularization Among Patients With End-Stage Renal Failure: Where Is the Journey Going, and How Far Have We Come?∗

Hans Henning Eckstein; Claudius Kuechle; Thomas Hans Werner Stadlbauer

doi:10.1016/j.jcin.2017.06.061

Trends in Lower Limb Revascularization Among Patients With End-Stage Renal Failure: Where Is the Journey Going, and How Far Have We Come?^∗

Hans Henning Eckstein, Claudius Kuechle, Thomas Hans Werner Stadlbauer

Technical University of Munich

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	2111-2112
Number of pages	2
Journal	JACC: Cardiovascular Interventions
Volume	10
Issue number	20
DOIs	https://doi.org/10.1016/j.jcin.2017.06.061
State	Published - 23 Oct 2017
Externally published	Yes

Keywords

end-stage renal failure
endovascular
lower limb
surgery

Access to Document

10.1016/j.jcin.2017.06.061

Cite this

@article{af87954260a94f44b5e3b73ce37087e8,

title = "Trends in Lower Limb Revascularization Among Patients With End-Stage Renal Failure: Where Is the Journey Going, and How Far Have We Come?∗",

keywords = "end-stage renal failure, endovascular, lower limb, surgery",

author = "Eckstein, {Hans Henning} and Claudius Kuechle and Stadlbauer, {Thomas Hans Werner}",

note = "Funding Information: Dr. Eckstein has received research funding from Bayer. Dr. Stadlbauer is a speaker for Bayer, Bristol-Myers Squibb, Pfizer, and Daiichi Sankyo. Dr. Kuchle has reported that he has no relationships relevant to the contents of this paper to disclose. ",

year = "2017",

month = oct,

day = "23",

doi = "10.1016/j.jcin.2017.06.061",

language = "English",

volume = "10",

pages = "2111--2112",

journal = "JACC: Cardiovascular Interventions",

issn = "1936-8798",

publisher = "Elsevier Inc.",

number = "20",

}

TY - JOUR

T1 - Trends in Lower Limb Revascularization Among Patients With End-Stage Renal Failure

T2 - Where Is the Journey Going, and How Far Have We Come?∗

AU - Eckstein, Hans Henning

AU - Kuechle, Claudius

AU - Stadlbauer, Thomas Hans Werner

N1 - Funding Information: Dr. Eckstein has received research funding from Bayer. Dr. Stadlbauer is a speaker for Bayer, Bristol-Myers Squibb, Pfizer, and Daiichi Sankyo. Dr. Kuchle has reported that he has no relationships relevant to the contents of this paper to disclose.

PY - 2017/10/23

Y1 - 2017/10/23

KW - end-stage renal failure

KW - endovascular

KW - lower limb

KW - surgery

UR - http://www.scopus.com/inward/record.url?scp=85031762402&partnerID=8YFLogxK

U2 - 10.1016/j.jcin.2017.06.061

DO - 10.1016/j.jcin.2017.06.061

M3 - Editorial

C2 - 29050630

AN - SCOPUS:85031762402

SN - 1936-8798

VL - 10

SP - 2111

EP - 2112

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

IS - 20

ER -

Trends in Lower Limb Revascularization Among Patients With End-Stage Renal Failure: Where Is the Journey Going, and How Far Have We Come?∗

Keywords

Access to Document

Other files and links

Cite this

Trends in Lower Limb Revascularization Among Patients With End-Stage Renal Failure: Where Is the Journey Going, and How Far Have We Come?^∗